The global stroke management market is anticipated to witness substantial growth through 2032, owing to the rising count of cardiovascular disease cases worldwide. In addition, shifting patient preference towards minimally invasive procedures is also expected to shape industry outlook. Such surgical procedures, such as endovascular thrombectomy, have seen a marked rise across healthcare facilities as they yield satisfactory clinical results.

Technological advancements in the field of medical devices is expected to bolster industry revenues as well. Minimally invasive procedures such as stereotactic surgery, use advanced imaging-based surgical localization with a 3-D roadmap systems, which help identify the clot and the suitable method for its removal.

In their efforts to further enhance patient outcomes, many industry players have started to marry technology with innovative surgical procedures. For instance, Cerebrotech Medical Systems, a neurotechnology device firm, introduced a product called Cerebrotech Visor, a VIPS technology-based device for neurological evaluation.

The device also received a CE mark in Europe for measuring stroke-related bioimpedance asymmetry. The company is further researching the device’s feasibility in certain brain pathologies including stroke.

The overall stroke management market landscape is classified into segments such as type, product, end-use, and regional landscape.

Based on type, the market is categorized into hemorrhagic, ischemic, transient ischemic attack (TIA), and others. The ischemic segment held the largest market share of over USD 30 billion in 2022, fueled by the rising cases of ischemic disease, especially among women.

In fact, as per the World Stroke Organization (WSO), women account for over half (51%) of all active cases of ischemic stroke globally. A 2020 study estimates that ischemic heart disease affects approximately 126 million people worldwide, which is 1.72% of the global population.

On the basis of product, the industry is bifurcated into diagnostic devices and therapeutic devices. The diagnostic devices segment is expected to witness substantial growth from 2023-2032, owing to increasing public health programs that encourage the population to undergo periodic screening examinations for the early detection of specific chronic diseases including cancer, cardiovascular diseases, and others.

Based on end-use, the industry is divided into ambulatory surgical centers, diagnostic centers, hospitals, and others. Amongst them, the diagnostic centers segment held a multi-billion revenue share in 2022, primarily owing to the rising occurrences of neurological and cardiovascular ailments across the globe.

As per CDC, every 34 seconds a person dies due to cardiovascular disease in the U.S. Many world governments are focusing on improving their diagnosis capabilities to prevent CVDs-related deaths.

Regionally, the industry is classified into Europe, Asia Pacific, North America, MEA, and LATAM. The North America stroke management industry accounted for a lion’s share of the overall market landscape in 2022, on account of the region’s robust healthcare sector.

Moreover, the sector is also witnessing a growing number of investments in recent years, which further shapes the regional outlook. Increasing per capita income of North America’s female population and rising urbanization are expected to deliver an additional capacity for growth to the market.